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Abstract: (1) Background: Our previous studies unveiled the hit thioxanthone TXA1 as an inhibitor of
P-glycoprotein (drug efflux pump) and of human tumor cells growth, namely of melanoma cells. Since
TXA1 is structurally similar to lucanthone (an autophagy inhibitor and apoptosis inducer) and to
N10-substituted phenoxazines (isosteres of thioxanthones, and autophagy inducers), this study aimed
at further assessing its cytotoxic mechanism and evaluating its potential as an autophagy modulator
in A375-C5 melanoma cells; (2) Methods: Flow cytometry with propidium iodide (PI) for cell cycle
profile analysis; Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay, flow
cytometry with Annexin V/PI labeling and Western blot for apoptosis analysis were conducted.
A pharmacophore approach was used for mapping TXA1 onto pharmacophores for autophagy
induction. Autophagy analyses included transmission electron microscopy for visualization of
autophagic structures, fluorescence microscopy for observation of monodansylcadaverine (MDC)
staining, pattern of LC3 expression in the cells and acridine orange staining, and Western blot for
autophagic proteins expression; (3) Results: TXA1 induced autophagy of melanoma cells at the
GI50 concentration (3.6 µM) and apoptosis at twice that concentration. Following treatment with
TXA1, autophagic structures were observed, together with the accumulation of autophagosomes and
the formation of autophagolysosomes. An increase in LC3-II levels was also observed, which was
reverted by 3-methyladenine (3-MA) (an early stage autophagy-inhibitor) but further increased by
E-64d/pepstatin (late-stage autophagy inhibitors). Finally, 3-MA also reverted the effect of TXA1
in cellular viability; (4) Conclusion: TXA1 decreases the viability of melanoma cells by modulation
of autophagy and may, therefore, serve as a lead compound for the development of autophagy
modulators with antitumor activity.
Molecules 2016, 21, 1343; doi:10.3390/molecules21101343 www.mdpi.com/journal/molecules
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1. Introduction
Autophagy is a catabolic process which targets cellular organelles and cytoplasmic constituents
to the lysosomes for degradation, allowing the cell to maintain homeostasis and being particularly
relevant during nutrient deprivation and other stresses [1]. Alterations in autophagy are frequently
found in diseases, such as cancer [2], and might be relevant for cancer response to therapy. Although
autophagy has been traditionally regarded as a pro-survival mechanism, it has also been related to cell
death [2,3]. In fact, a cross-talk between autophagy and apoptosis has been documented, with these
pathways sharing various mediators [4–6].
The effect of autophagy in cancer therapy is still under debate and may depend on several
factors, such as the cellular context, as well as on the levels and duration of cellular autophagy [7,8].
Indeed, targeting autophagy may provide new opportunities for cancer drug discovery. Several small
molecules which modulate autophagy have been already described [8–10]. Interestingly, promotion
of cell death for cancer therapy has been observed not only with autophagy inducers, but also with
autophagy inhibitors [11].
The use of autophagy inhibitors, such as chloroquine, hydroxychloroquine, and lucanthone,
in association with chemotherapeutic agents, has already reached clinical trials [7]. On the other
hand, the use of small molecules that promote autophagy has also been shown to induce cell death
in cancer cells [8]. Indeed, resveratrol was shown to induce cell death in several human tumor cell
lines by triggering both autophagy and apoptosis [12–14]. In addition, imatinib (Gleevec), a known
inducer of apoptosis, was shown to activate the cellular autophagy machinery in mammalian cell lines,
including chronic myelogenous leukemia cells [15]. Furthermore, tetrahydrocannabinol was reported
as an inducer of cell death by activating autophagy in glioma cells [16]. Likewise, curcumin [17],
as well as some of its derivatives [18–20], were shown to activate autophagy in human cancer cell
lines. Additionally, a novel small molecule (STF-62247) was shown to promote autophagic cell death
in Von Hippel Lindau (VHL)-deficient renal cell carcinoma cells [21]. Finally, phenethyl isothiocyanate
suppressed the Akt/mTOR pathway in human prostate cancer cell lines, leading to several autophagic
features [22].
In previous studies from our group, the thioxanthone TXA1 has emerged as a hit compound,
modulating P-glycoprotein activity in chronic myeloid leukemia cells [23], inhibiting human tumor
cell growth and inducing apoptosis [23,24]. This compound has been shown to be particularly potent
in melanoma cells [24].
Since the mechanism of action of this hit molecule is still not fully understood and since TXA1 was
structurally similar to molecules known to modulate autophagy (lucanthone and to N10-substituted
phenoxazines) [25,26], this study aimed at further assessing the cytotoxic mechanism of TXA1 in
A375-C5 melanoma cells, particularly at further evaluating its potential as an autophagy modulator.
2. Results
2.1. Treatment of A375-C5 Melanoma Cells with Twice the GI50 Concentration of TXA1 Alters the Cell Cycle
Profile and Induces Apoptosis Although No Effect Is Found with the GI50 Concentration
The effect of TXA1 on the A375-C5 cell cycle profile was analyzed, testing two concentrations of
this molecule: the previously-determined GI50 concentration (3.6 µM) [24] and twice this concentration
(2 × GI50). Results showed that treatment with 3.6 µM of TXA1 did not cause any major alterations in
the cell cycle profile (Figure 1) but pronounced alterations in the cell cycle profile were observed with
the highest concentration tested (7.2 µM). In particular, a strong increase in the sub-G1 population
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was observed when cells were treated with this concentration, which suggested that TXA1 induces
apoptosis at this higher concentration, but not at the GI50 concentration.Molecules 2016, 21, x  3 of 14 
 
Figure 1. The effect of TXA1 on the cell cycle profile of A373-C5 cells. Cells were treated for 48 h with 
medium (blank), with TXA1 (3.6 μM and 7.2 μM), or with the corresponding DMSO concentrations 
(DMSO 1 and DMSO 2, respectively). (A) Representative images of flow cytometry analyzed following 
DNA staining with propidium iodide (PI). Left panels correspond to dot plots of forward vs. side scatter 
(FSC vs. SSC) and show the gated population. Right panels correspond to the histograms with cell cycle 
profile of the gated population, following the exclusion of cellular aggregates and debris (data not shown); 
(B) The percentage of cells in the different cell cycle phases. Results are the mean ± SEM of four independent 
experiments. * p < 0.05 blank vs. treatment. Etoposide (2 μM) was used as positive control: G0/G1: 
6.3% ± 2.0%; S: 10.4% ± 2.3%; G2/M: 78.3% ± 0.7%. 
Figure 1. The effect of TXA1 on the cell cycle profile of A373-C5 cells. Cells were treated for 48 h with
medium (blank), with TXA1 (3.6 µM and 7.2 µM), or with the corresponding DMSO concentrations
(DMSO 1 and DMSO 2, respectively). (A) Representative images of flow cytometry analyzed following
DNA staining with propidium iodide (PI). Left panels correspond to dot plots of forward vs. side
scatter (FSC vs. SSC) and sh w the gated pop lati n. Right panels correspon o the histograms
with cell cycle profil of the gated population, following he exclusion of cellular aggregates and
debris (data not shown); (B) The percentage of cells in the different cell cycle phases. Results are the
mean ± SEM of four independent experiments. * p < 0.05 blank vs. treatment. Etoposide (2 µM) was
used as positive control: G0/G1: 6.3% ± 2.0%; S: 10.4% ± 2.3%; G2/M: 78.3% ± 0.7%.
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Induction of apoptotic cell death following treatment with 7.2 µM of TXA1 (but not
with 3.6 µM) was further confirmed with the Terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) assay (Figure 2A) and by flow cytometry analysis following Annexin V/FITC
and PI staining (Figure 2B). Results from both of these assays clearly showed that treatment
with 7.2 µM of TXA1 strongly induced cell death by apoptosis, although no alterations were observed
following treatment with 3.6 µM TXA1 (GI50 concentration). These results were further corroborated
by the analysis of PARP cleavage in these cells, by Western blot (Figure 2C). Indeed, a very strong
increase in PARP cleavage was detected only following treatment with the highest TXA1 concentration
tested (7.2 µM).
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(DMSO 1 and DMSO 2, respectively). (A) Levels of programmed cell death were analyzed with the 
TUNEL assay. Etoposide (1 μM) was used as a positive control (4% ± 0.1% of programmed cell death). 
* p < 0.05 Blank vs. treatment (B) Flow cytometry analysis of apoptotic cell death following Annexin 
V-FITC/PI staining. Images are representative of three independent experiments (values correspond 
to the mean ± SEM). Etoposide (1 μM) was used as positive control (18% ± 1.4% apoptosis); (C) PARP 
levels were analyzed by Western blot. Image is representative of 4 independent experiments (left panel). 
Densitometry analysis of the Western blots is expressed after normalization of the values obtained for 
each protein with the values obtained for tubulin (in relation to blank cells) and represent the mean ± 
SEM from four independent experiments (right panel). 
2.2. TXA1 Maps onto a Pharmacophore for Autophagy Induction 
Given the similarity of TXA1 with N10-substituted phenoxazines (isosteres of thioxanthones which 
were described as autophagy inducers [26]) and since a pharmacophore had been previously developed 
for autophagy induction using these compounds [26], the possibility of the involvement of autophagy 
in the mechanism of action of TXA1 was considered using a pharmacophore approach. This was carried 
out using the referred pharmacophore and verifying its ability to identify autophagy inducers with 
different scaffolds from those it had been created from. TXA1 was mapped to the tree-feature 
pharmacophore (Figure 3) with results showing that TXA1 fits the pharmacophore for autophagy 
induction in 125 possible conformations. In all of the conformations, the nitrogen from the tertiary 
Figure 2. The effect of TX 1 on cell death by apoptosis of 373-C5 cells. Cells ere treated for 48 h
ith ediu (blank), T 1 (3.6 µ and 7.2 µ ), or ith the corresponding S concentrations
( S 1 an S 2, res ectively). ( ) evels of rogra e cell eath ere analyze ith the
assa . t si e (1 µ ) as se as a siti e c tr l (4 0.1 of progra e cell death).
* . l s. tre t e t ( ) l c t etr l sis f t tic cell e t f ll i e i
- I I t i i . I r representative of thre independent experiments (values correspond to
the mean ± SEM). Etoposide (1 µM) was used as positive control (18% ± . t i ); ( )
l l l l . i i i t ri ts (left panel).
analysis of the Western blots is expressed after normalization of the values obtained
for each protein with the values obtained for tubulin (in relation to blank cells) and repr sent the
mean ± SEM from four independent xperiments (right panel).
2.2. T 1 aps onto a Phar acophore for utophagy Induction
iven the similarity of TXA1 with N10-substituted phenoxazines (isosteres of thioxanthones
hich were described as autophagy inducers [26]) and since a pharmacophore had been previously
developed for autophagy induction using these compounds [26], the possibility of the involvement
of autophagy in the mechanism of action of TXA1 was considered using a pharmacophore approach.
This was carried out using the referred pharmacophore and verifying its ability to identify autophagy
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inducers with different scaffolds from those it had been created from. TXA1 was mapped to the
tree-feature pharmacophore (Figure 3) with results showing that TXA1 fits the pharmacophore
for autophagy induction in 125 possible conformations. In all of the conformations, the nitrogen
from the tertiary amine fits the positive ionizable group (red sphere on Figure 3). In 90% of the
mapped conformations, one aromatic ring from the thioxanthonic scaffold fits one of the hydrophobic
features, whereas the propoxyl carbonated chain fits the remaining hydrophobic feature (blue spheres
on Figure 3).
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2.3. The GI50 Concentration of TXA1 Induces A375-C5 Cellular Autophagy
The possible involvement of autophagy in the TXA1 mechanism of action was evaluated in vitro,
in the A375-C5 cells. The GI50 concentration of TXA1 (3.6 µM) was selected to carry out these studies,
in order to avoid alterations in apoptosis or in the cell cycle profile (observed above when using
the 7.2 µM treatment but not the 3.6 µM treatment).
The ultrastructural analysis (by transmission electron microscopy) of A375-C5 cells treated
with 3.6 µM TXA1 showed the presence of autophagic structures (whereas the presence of such
structures was very seldom seen in control cells) (Figure 4A). In agreement with this, MDC staining
of A375-C5 cells following treatment with 3.6 µM TXA1 showed a clear punctate accumulation of
MDC, indicating the presence of autophagosomes (Figure 4B). Other assays further confirmed the
involvement of autophagy in the mechanism of action of TXA1. Indeed, transfection of A375-C5 cells
with a mCherry-LC3 (microtubule-associated protein 1 light chain 3) expression vector allowed further
visualization of the presence of LC3-II in autophagosomes, with a punctuated LC3 expression pattern
being evident in transfected cells following TXA1 treatment (Figure 4B). Moreover, the formation
of autophagolysosomes following TXA1 treatment was confirmed by fluorescence microscopy
following staining with acridine orange. Indeed, results showed that untreated control cells presented
predominantly green fluorescence with very minimal red fluorescence, whereas cells treated with
TXA1 displayed considerable red fluorescence, typical of acidic vacuolar organelles (Figure 4B).
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acridine orange incorporation (orange-red). Cell nuclei are stained with DAPI (blue). Bar = 20 μm. 
Images are representative of two experiments (except for MDC assay which is representative of three 
experiments). 
Figure 4. The effect of TXA1 on A375-C5 cellular autophagy. Cells were treated for 48 h with
medium (blank), TXA1 (3.6 µM) or with the corresponding concentration of DMSO. (A) Transmission
electron microscopy (TEM). Images are representative of two independent experiments. Arrows
indicate autophagic structures. Bar corresponds to 1 µm; (B) Fluorescence microscopy analysis after
(top panel) MDC staining (green); (middle panel) transfection with LC3-mCherry vector (red);
and (lower panel) acridine orange incorporation (orange-red). Cell nuclei are stained with DAPI
(blue). Bar = 20 µm. Images are representative of two experiments (except for MDC assay which is
representative of three experiments).
Moreover, LC3-II levels were also analyzed by Western blot (Figure 5A). Results showed an
increase in LC3-II levels following treatment with 3.6 µM TXA1, further indicating that TXA1 modulates
autophagy in A375-C5 cells.
To further understand if TXA1 was an inducer or an inhibitor of autophagy, treatment with
this compound was carried out in the presence of 3-methyl adenine (3-MA, a selective inhibitor of
the early stages of autophagy [27]) or with E-64d/pepstatin (lysossomal protease inhibitors which
inhibits autophagy at the later stage), to assess the autophagic flux [28–30]. Results showed that 3-MA
treatment clearly reduced the levels of LC3-II induced by TXA1 (Figure 5B), supporting the idea that
TXA1 was an inducer of autophagy. Furthermore, an additive increase in the levels of LC3-II was
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observed after co-treatment with E-64d/pepstatin, when compared to TXA1 treatment alone, showing
that the autophagic flux was occurring in TXA1-treated cells. Thus, it may be concluded that TXA1 is
an inducer of autophagy.Molecules 2016, 21, x  7 of 14 
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that it plays dual roles in cancer, acting also as a tumor suppressor mechanism, or even as a cell death 
Figure 5. Effect of TXA1 on the expression levels of LC3-II in A375-C5 cells. Cells were treated
for 48 h with medium (blank), TXA1 (3.6 µ or 7.2 µM), or with the corresponding DMSO
concentrations (DMSO or DMSO2, respectively) LC3-II protein levels were analyzed by Western
blot. (A) Following treatment with TXA1 alone; (B) following co-treatment with 3-MA;
and (C) following co-treatment with E-64d/pepstatin. Images are representative of, at least,
three independent experiments (except for the case of blank and DMSO treatments in the presence
of E-64d/pepstatin, which result from two experiments only). Results of the densitometry analysis
are expressed after normalization of the values o t i e f r each protein with the values obtaine
for tubulin r actin (and furth r expressed in relation to blank cells) and represent the mean ± SEM
from, at least, three indepe dent experiments (except for the case of blank and DMSO treatments in the
presence of E-64d/pepstatin, which result from two exp riments only). * p ≤ 0.05 Blank vs. treatment.
A similar autophagic effect was observed for TXA1 hydrochloride (TXA1.HCl) on a breast
adenocarcinoma cell line, with increases in the autophagic structures and LC3-II levels (Supplementary
Figure S2).
Finally, the effect of cellular co-treatment with TXA1 and 3-MA was verified on viable cell
numbers, in order to confirm whether the induction of autophagy by TXA1 was responsible for the
cytotoxic effect of this molecule. As expected, treatment with 3-MA alone had no effect on A375-C5
viable cell numbers (Figure 6). However, the presence of 3-MA reverted the cytotoxic effect of TXA1,
proving that the cytotoxic effect of TXA1 is dependent on autophagy induction.
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3. Discussion
Although autophagy is mainly considered a survival mechanism, there is increasing evidence
that it plays dual roles in cancer, acting also as a tumor suppressor mechanism, or even as a cell
death mechanism. This may depend not only on the cellular context, but also on the levels and
duration of cellular autophagy [7,8,31]. Excessive or sustained autophagy has the potential to induce
tumor cell death and this may explain the antitumor effect of autophagy inducers [7,8]. Indeed,
several antineoplastic agents have been described to induce autophagy, leading to cell death [32].
These agents include conventional cytotoxic drugs, as well as molecularly-targeted anticancer
drugs, such as imatinib [15,31], cetuximab [33], and histone deacetylase (HDAC) inhibitors [34].
Thus, there is increasing interest in the development of compounds which modulate autophagy for
anticancer therapy.
We have been studying thioxanthonic molecules and derivatives, since their heterocyclic
scaffold has been associated with several biological properties, including anti-parasitic, anti-oxidative,
and antitumor activities [35]. In our previous studies, TXA1 has emerged as a hit thioxanthone
presenting tumor cell growth inhibitory activity towards several human tumor cell lines. In addition,
it has also been verified that TXA1 did not affect the growth of non-tumor MRC5 cells [23,24].
This compound presented a 2-(diethylamino)ethylamine side chain located at position 1 which
was identical to the amine in the same position of lucanthone, the first thioxanthone described as
a potential antitumor agent (originally used as an anti-schistosomal drug) which reached clinical
trials [35,36], being currently in Phase II clinical trials for glioblastoma multiforme [37]. Moreover,
TXA1 was also structurally similar to N10-substituted phenoxazines (isosteres of thioxanthones).
Interestingly, autophagy modulation had been previously described for both lucanthone (described as a
chemo- and radio-sensitizer associated with autophagy inhibition [25]) and for N10-substituted
phenoxazines (described as inducers of autophagy [26]). Considering the structural similarity of
TXA1 with the referred compounds, the present study explored the mechanism of action of TXA1 in
melanoma cells, particularly regarding the modulation of autophagy.
A promising association of TXA1 to the autophagic process resulted from the fact that
TXA1 fitted a pharmacophore for autophagy induction in 125 possible conformations (Figure 3).
When analyzing the effect of this compound in vitro, in A375-C5 cells, while not inducing apoptosis
(or affecting cell cycle profile) at the GI50 concentrations, this treatment caused a clear accumulation
of autophagic structures. This was observed not only by TEM (Figure 4A), which is described as a
gold standard method for autophagy detection [30], but also by the increase in MDC staining and
LC3 punctate pattern (Figure 4B). Autophagy modulation by TXA1 was further confirmed by the
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conversion of the LC3 from the cytosolic form (LC3-I) into the autophagosome-associated form (LC3-II),
which is considered a marker for autophagy (observed by Western blot, Figure 5) [38,39]. Moreover,
this increase in LC3-II levels following TXA1 treatment was reverted in the presence of the early-stage
autophagy inhibitor 3-MA (Figure 5B).
Nonetheless, the observation of an increase in the LC3-II levels could be due to an induction
of autophagy or to an inhibition of the autophagic flux. One common strategy to evaluate this is
by analyzing LC3-II levels, by Western blot, in the presence and absence of lysosomal degradation
inhibitors [29,30]. The fact that the presence of these inhibitors (E-64d/pepstatin) further increased
LC3-II levels when compared to treatment with TXA1 alone (Figure 5C), showed that TXA1 promoted
an increase in the autophagic flux. Moreover, acridine orange staining further corroborated these
results by showing the presence of acidic structures, such as autophagolysosomes, in TXA1-treated
cells (Figure 4B).
Finally, the cytotoxicity of TXA1 (3.6 µM) in A375-C5 cells was reverted by the inhibition
of autophagy with 3-MA (Figure 6). Indeed, this compound is a widely accepted inhibitor
of autophagosome formation, acting through the inhibition of class III phosphatidylinositol 3
(PI3)-kinase [8]. Several other studies have also described the use of 3-MA to investigate the
involvement of autophagy in the cytotoxic effect of different molecules/natural extracts [40–43].
In the present study, in addition to the reversion of the increase in LC3 II levels induced by TXA1,
pretreatment with 3-MA also rescued A375-C5 cellular viability, further supporting the role of
autophagy in the cytotoxic effect of TXA1 in these cells.
4. Materials and Methods
4.1. Compound
TXA1, 1-{[2-(diethylamino)ethyl]amino}-4-propoxy-9H-thioxanthen-9-one, has been previously
synthesized by our group as described [23]. Its purity was determined by High-Performance Liquid
Chromatography with Diode-Array Detection (HPLC-DAD) analysis using an isocratic elution of
MeOH/H2O basified with triethylamine (TEA) (1%) at a constant flow rate of 1.0 mL/min [23].
A 60 mM stock solution was prepared in DMSO and stored at −20 ◦C.
4.2. Mapping of TXA1 onto Pharmacophores for Autophagy Induction
A common feature pharmacophore model was created using HipHop module of Catalyst
(Accelrys 2.1, San Diego, CA, USA) in order to reproduce a pharmacophore for autophagy induction, as
previously described by Tsvetkov et al. [26]. This pharmacophore is composed of one positive ionizable
group and two hydrophobic groups. TXA1 was subjected to energy minimization using HyperChem
version 8.0 (Gainesville, FL, USA). The semi-empirical AM1 (Austin Model 1) [44] method with the
Polak-Ribière algorithm was employed for molecular minimization [45]. The mapping of TXA1 onto
the three-feature previously-described pharmacophore for autophagy induction was performed using
the “Best Fit” method in Catalyst. During the flexible fitting process, conformations on TXA1 were
calculated within the 20 kcal/mol energy threshold. Maximum omitted features were set to zero.
4.3. Cell Culture
The A375-C5 melanoma cell line (ECACC, Salisbury, UK) was genotyped at IPATIMUP´s
Parentage and Genetic Identification Services Unit, using a PowerPlex® 16 HS System
(Promega, Fitchburg, MA, USA) according to International Society for Forensic Genetics (ISFG)
guidelines. Cells were routinely cultured in RPMI-1640 with UltraGlutamine I and 25 mM
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer (Lonza, Basel, Switzerland)
supplemented with 10% FBS (Fetal Bovine Serum, PAA, Cölbe, Germany), and maintained in a
humidified incubator at 37 ◦C with 5% CO2. Cell number and viability were determined with trypan
blue exclusion assay.
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4.4. Cell Treatment with TXA1
Cells were plated in six-well plates (1 × 105 cells/well) and allowed to adhere for 24 h. Cells
were then treated with the previously-determined GI50 concentration (3.6 µM) [24] and with twice that
concentration (2 × GI50, 7.2 µM) of TXA1. Control treatments were included, such as: untreated cells
(blank); cells treated with DMSO as a negative control (corresponding to the volume used for the GI50
(DMSO 1) or for the 2 × GI50 (DMSO 2) concentrations); cells treated with etoposide (Sigma-Aldrich,
St. Louis, MO, USA) as a positive control for cell death and cell cycle analysis; and, finally, cells under
serum starvation (i.e., without FBS), as a positive control for autophagy induction. Following the
indicated time points (see Figure legends), cell number and viability were determined with the trypan
blue exclusion assay and cells were further processed according to the following procedures.
4.5. Cell Cycle Profile
Cells were fixed in 70% ice-cold ethanol and subsequently resuspended in 0.1 mg/mL RNase A
and 5 µg/mL propidium iodide in PBS for 1 h. Cellular DNA content was measured by flow cytometry
using a FACSCalibur flow cytometer (BD Biosciences, Erembodegem, Belgium). The percentage
of cells in the different phases of the cell cycle and in the sub-G1 peak were determined using
FlowJo 7.6.5 software (Tree Star, Inc., Ashland, OR, USA) after cell debris and aggregate
exclusion [23,46] and plotting at least 10,000 events per sample.
4.6. Programmed Cell Death
TUNEL assay was carried out using the “In situ cell death detection kit—fluorescein” (Roche,
Boulogne-Billancourt Cedex, France) as previously described [47,48]. Briefly, cells were fixed in 4%
paraformaldehyde (PFA) and cytospins were prepared. Cells were then permeabilized in ice-cold 0.1%
Triton X-100 in 0.1% sodium citrate and incubated with TUNEL reaction mixture (enzyme dilution
1:20). Slides were mounted in Vectashield Mounting Media with DAPI (Vector Laboratories Inc.,
Burlingame, CA, USA), observed in a DM2000 fluorescence microscope (Leica, Wetzlar, Germany)
and a semi-quantitative evaluation was performed by counting a minimum of 500 cells per slide.
In addition, a specific assay for apoptosis was carried out using the “Human Annexin-V-FITC/PI
apoptosis” kit (Bender MedSystems, Vienna, Austria) as previously described [49]. All flow
cytometry analyses were performed using the FACSCalibur flow cytometer (BD Biosciences), plotting
at least 10,000 events per sample and using the FlowJo 7.6.5 software (Tree Star, Inc.).
4.7. Expression of Apoptotic and Autophagic Proteins
Cells were lysed in Winman’s buffer (1% NP-40, 0.1 M Tris-HCl pH 8.0, 0.15 M NaCl, and 5 mM
EDTA) supplemented with a protease inhibitor cocktail (Roche). Protein lysates were quantified using
a DC™ Protein Assay kit (Bio-Rad, Hercules, CA, USA), according to the manufacturer’s instructions
and 20 µg of protein loaded on 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) gel [50,51]. After electrophoretic transfer into nitrocellulose membranes (Amersham,
Cleveland, OH, USA), membranes were incubated with the following primary antibodies: rabbit
anti-poly (ADP-ribose) polymerase PARP (H-250), (1:2000, Santa Cruz Biotechnology, Heidelberg,
Germany), rabbit anti-light chain 3 B, LC3 (1:1000, Cell Signaling, Leiden, Netherlands), goat anti-actin
antibody (1:2000, Santa Cruz Biotechnology), or mouse anti-tubulin antibody (1:10,000, Sigma-Aldrich),
and with the corresponding secondary antibodies: goat anti-rabbit IgG-HRP (1:2000, Santa Cruz
Biotechnology), donkey anti-goat IgG-HRP (1:2000, Santa Cruz Biotechnology), or goat anti-mouse
IgG-HRP (1:2000, Santa Cruz Biotechnology). Signals were detected using Amersham™ ECL Western
blotting detection reagents (GE Healthcare, Cleveland, OH, USA), Amersham Hyperfilm ECL
(GE Healthcare) and Kodak GBX developer and fixer (Sigma-Aldrich).
Molecules 2016, 21, 1343 11 of 15
4.8. Monodansylcadaverine (MDC) and Acridine Orange Staining
For MDC staining, studies were carried out following 48 h incubation with 3.6 µM of TXA1
(or controls). Cells were incubated for 1 h with freshly prepared MDC (50 µM) and fixed as described
above. For acridine orange staining, cells were incubated with acridine orange (1 µM) for 15 min.
In both cases, cytospins were prepared and mounted in Vectashield Mounting Media with DAPI
(Vector Laboratories Inc., Burlingame, CA, USA). Cells were observed using a fluorescence microscope
(Axio Imager.Z1 coupled with ApoTome Imaging System microscope, Zeiss, (Oberkochen, Germany).
4.9. Transfection with LC3-mCherry Expression Vector
Cells were plated in culture slides (Falcon; 2 × 104 cells/well) and allowed to adhere for 24 h.
Transfection with LC3-mCherry vector (a kind gift from T. Johansen [52]) was then carried out using
lipofectamine (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. During
the initial 4 h transfection, cells were incubated with medium with 5% FBS, then replaced by medium
with 10% FBS [53]. Following 24 h transfection, cells were treated for 48 h with 3.6 µM of TXA1 or with
controls (blank and DMSO). Cells were then fixed in 4% PFA in PBS and analyzed in a fluorescence
microscope (Axio Imager.Z1 coupled with ApoTome Imaging System microscope, Zeiss).
4.10. Transmission Electron Microscopy
Following 48 h incubation with 3.6 µM TXA1 (or controls), cells were fixed with 2% glutaraldehyde
and 2% PFA in 0.1 M phosphate buffer (PB), washed with 0.1% Millipore-filtered PB tannic acid,
post-fixed with 1% PB osmium tetroxide for 1 h, and stained with 1% Millipore-filtered uranyl acetate.
Samples were dehydrated in increasing concentrations of ethanol and, finally, in propylene oxide
for 30 min. Samples were then infiltrated and embedded directly in Epon resin and polymerized
in a 70 ◦C oven for two days. Cuts were performed on ultrathin (50–100 nm) sections with a Leica
(Wetzlar, Germany) Ultracut microtome and each section was stained with 5% uranyl acetate solution
and with Reynold’s lead citrate solution. Images were examined in a Jeol JEM 1400 transmission
electron microscope (Tokyo, Japan) at an accelerating voltage of 80 kV. Digital images were obtained
using a Gatan SC 1000 ORIUS CCD camera (Warrendale, PA, USA).
4.11. Treatment with Autophagy Inhibitors
Cells were plated in six-well plates (1 × 105 cells/well) and allowed to adhere for 24 h. Cells
were then treated for 1 h with 0.5 mM 3-methyladenine (3-MA, Sigma) or with 10 µg/mL E-64d
(AppliChem, Darmstadt, Germany) and Pepstatin A (Cayman Chemical, Ann Arbor, MI, USA) and
then co-incubated with 3.6 µM of TXA1, or with control treatments (blank, DMSO) for 48 h. Viable cell
numbers were then assessed by trypan blue assay and protein expression analyzed by Western blot,
as described above.
4.12. Statistical Analysis
Results are expressed as mean ± standard error. Values for each treatment (or solvent) were
compared by Student’s t-test, and the differences were considered statistically significant if p ≤ 0.05.
5. Conclusions
This work reinforces the anticancer potential of the hit thioxanthonic small molecule TXA1.
In particular, it shows that this compound decreases the viability of human tumor cell lines by inducing
autophagy. Therefore, TXA1 may serve as lead compound for the development of new autophagy
modulators with antitumor activity. Future work will allow to further elucidate the intracellular
signaling cascades associated with the effect of TXA1 in autophagy, such as the phosphatidylinositol
3-kinase/mammalian target of rapamycin (PI3K/mTOR) or the AMP-activated protein kinase (AMPK)
signaling pathways [11]. Furthermore, future studies with human tumor xenograft models in
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nude mice will allow confirmation of the in vivo lack of toxicity and antitumor potential of this
hit compound.
Supplementary Materials: Supplementary materials can be accessed at: http://www.mdpi.com/1420-3049/21/
10/1343/s1.
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